Calamos Advisors LLC Has $18.15 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Calamos Advisors LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 42.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 160,324 shares of the medical equipment provider's stock after selling 118,465 shares during the quarter. Calamos Advisors LLC owned about 0.08% of Zimmer Biomet worth $18,145,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Garde Capital Inc. acquired a new stake in shares of Zimmer Biomet in the first quarter worth $29,000. Menard Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $30,000. Washington Trust Advisors Inc. acquired a new stake in shares of Zimmer Biomet in the first quarter worth $30,000. Accredited Wealth Management LLC acquired a new position in Zimmer Biomet during the 4th quarter valued at $36,000. Finally, OFI Invest Asset Management acquired a new position in Zimmer Biomet during the 4th quarter valued at $40,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Price Performance

NYSE ZBH traded up $0.17 on Friday, hitting $93.67. 927,032 shares of the company were exchanged, compared to its average volume of 1,811,399. The firm has a 50 day moving average of $94.04 and a two-hundred day moving average of $101.76. The company has a market cap of $18.53 billion, a P/E ratio of 20.72, a P/E/G ratio of 2.17 and a beta of 0.71. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. The business had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The firm's quarterly revenue was up 1.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.94 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a yield of 1.02%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.39% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on ZBH. Royal Bank Of Canada cut their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a report on Monday, April 14th. Canaccord Genuity Group lowered their price target on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Robert W. Baird lowered their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities lowered their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $111.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.